Oxiris: The only set for 3-in-1 CRRT-Sepsis Management

**UNIQUE MEMBRANE TECHNOLOGY PROVIDES 3-FOLD MODE OF ACTION**

A. Heparin coating: reduces membrane thrombogenicity*
B. PEI** surface treatment: adsorbs endotoxin***
C. AN69 base membrane: adsorbs cytokines and toxins while providing continuous renal support. Cytokine adsorption occurs throughout the entire membrane thickness

** PEI PolyEthylentimine
*** Endotoxin: lipopolysaccharide complex associated with outer membranes of Gram-negative bacteria

---

**CRRT and sepsis management using a single device**

- One filter for both cytokine and endotoxin removal while simultaneously supporting renal function and fluid management17
- No change to CRRT set up and delivery — reduces need for additional staff training
- Use with familiar Prismaflex and Prisma systems with the same setup as traditional CRRT17
- No additional equipment required for removal of inflammatory mediators

**Potential to reduce workload**

- Heparin-grafted membrane may help to provide clinically acceptable filter签约 with potential to minimise treatment interruptions and support adequate dialysis dose delivery19

---

**Oxiris 3-in-1: Designed to simplify CRRT-Sepsis Management**

**Diagram is for illustrative purposes only**

Note: For safe and proper use refer to the Instructions for Use (IFU)17

---

Baxter, AN 69, Oxiris, PrisMax and Prismaflex are trademarks of Baxter International Inc. or its subsidiaries. CytoSorb is a trademark of CytoSorbents Inc.
The association between indicators of clinical status and removal of inflammatory mediators and endotoxin is uncertain. Findings from observational studies suggest that for some patients with sepsis-induced AKI, CRRT using the Oxiris membrane may have a positive effect on organ function and haemodynamic stability. Findings from preclinical, single-arm, and small observational studies have not been confirmed in larger, well-designed observational studies or randomized controlled trials. Some data are preliminary and have not been peer reviewed.

### Oxiris 3-in-1: Potential impact on organ function and haemodynamic stability

In patients with sepsis and AKI, CRRT with the Oxiris set may reduce circulating levels of specific inflammatory mediators and improve organ function and haemodynamic stability.

#### Oxiris 3-in-1: Potential improvements in organ function following CRRT with the Oxiris membrane in patients with sepsis-induced AKI

- Increased mean arterial pressure following CRRT with the Oxiris membrane in patients with sepsis-induced AKI
- Potential for improved organ function and haemodynamic stability as shown by reduction in SOFA score and increased MAP

#### Oxiris 3-in-1: Potential improvements in organ function following CRRT with the Oxiris membrane in patients with sepsis-induced AKI

The association between indicators of clinical status and removal of inflammatory mediators and endotoxin is uncertain.

### Oxiris 3-in-1: The only set that removes both cytokines and endotoxin

- Efficient removal of endotoxin with the Oxiris set according to in vitro benchmark studies
- The Oxiris membrane has strong endotoxin adsorptive capacity

### Oxiris 3-in-1: Potential improvements in organ function and haemodynamic stability

- Potential for improved organ function and haemodynamic stability
- The association between indicators of clinical status and removal of inflammatory mediators and endotoxin is uncertain.

### Oxiris 3-in-1: Potential improvements in organ function following CRRT with the Oxiris set in patients with sepsis-induced AKI

Findings from observational studies suggest that for some patients with sepsis-induced AKI, CRRT using the Oxiris membrane may have a positive effect on organ function and haemodynamic stability. Findings from preclinical, single-arm, and small observational studies have not been confirmed in larger, well-designed observational studies or randomized controlled trials. Some data are preliminary and have not been peer reviewed.